Coherus Oncology, Inc. Common Stock

$1.595
USD
Last updated on --.
24h volume1.53M
24h highest1.6750 USD
24h lowest1.5800 USD
24h Price movement+0.31%

CHRS recent prices

24 Hours
+0.31%+$0.005
30 days
-11.39%-$0.205
60 days
-8.33%-$0.145
90 days
-3.33%-$0.055

Key data

Previous close1.5900 USD
Market cap256.05M USD
Volume1.53M
P/E ratio1.370000
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)1.2100 USD
Net income (FY)-172.66M USD
Revenue (FY)46.88M USD
Last report dateMay 11, 2026

About Coherus Oncology, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersREDWOOD CITY
Employees (FY)145.00
Revenue per employee (FY)323.33K USD
Net income per employee (FY)-1.19M USD
Listed onNasdaq
Official website

CHRS conversion tables

CHRSCHRS
USDUSD
0.5 CHRS0.7975 USD
1 CHRS1.595 USD
5 CHRS7.975 USD
10 CHRS15.95 USD
USDUSD
CHRSCHRS
0.5 USD0.31348 CHRS
1 USD0.62696 CHRS
5 USD3.134 CHRS
10 USD6.269 CHRS

FAQ

CHRS is trading at $1.595, +0.31% over the last 24 hours. Track live moves on the price chart at the top of this page.
The CHRS stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. CHRS is currently trading at $1.595, +0.31% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on CHRS price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. CHRS's P/E ratio is currently 1.370000 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from CHRS; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against CHRS's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Coherus Oncology, Inc. Common Stock's market cap is currently 256.05M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume1.53M
24h highest1.6750 USD
24h lowest1.5800 USD
24h Price movement+0.31%
CHRSCHRS
USDUSD
Start trade with CHRS Perpetual